Shares of Sarepta Therapeutics SRPT nosedived 35.9% on Friday following the death of a patient dosed with one of its ...

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

Across the recent three months, 26 analysts have shared their insights on Sarepta Therapeutics (NASDAQ:SRPT), expressing a variety of opinions spanning from bullish to bearish.The table below ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT – Research Report), Intercept Pharma (ICPT – Research Report) and ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Detailed price information for Alpha Teknova Inc (TKNO-Q) from The Globe and Mail including charting and trades.

Explore Sarepta Therapeutics analyst ratings and price targets (NASDAQ:SRPT) on Benzinga. Stay updated on expert opinions and forecasts for SRPT stock.

Sarepta Therapeutics (SRPT) closed the last trading session at $143.78, gaining 16.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...

Throughout the last three months, 12 analysts have evaluated Sarepta Therapeutics (NASDAQ:SRPT), offering a diverse set of opinions from bullish to bearish.The table below provides a concise ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report), AlloVir (ALVR – Research Report) and Bristol-Myers Squibb (BMY ...